BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21875484)

  • 1. [Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
    Xu CA; Su H; Liu JL; Li L; Zou HW
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):436-41. PubMed ID: 21875484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
    Zhao LD; Li JL; Wang Y; Wang B; Wang HY; Hao XZ; Cui CX; Zhang XR; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):217-21. PubMed ID: 21575523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
    Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
    Anticancer Res; 2014 Jun; 34(6):3205-10. PubMed ID: 24922695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
    Zhang RX; Cai DY; Wu XH; Hua D
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):869-72. PubMed ID: 23291140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].
    Wang Q; Zheng H; Hu F; Zhang H; Hu Y; Li J; Zhang T; Liu Z; Lu B; Hu A; Li B
    Zhongguo Fei Ai Za Zhi; 2016 Aug; 19(8):550-8. PubMed ID: 27561807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Ishikawa N; Hattori N; Yokoyama A; Tanaka S; Nishino R; Yoshioka K; Ohshimo S; Fujitaka K; Ohnishi H; Hamada H; Arihiro K; Kohno N
    Int J Cancer; 2008 Jun; 122(11):2612-20. PubMed ID: 18324627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
    Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients.
    Facchinetti F; Aldigeri R; Aloe R; Bortesi B; Ardizzoni A; Tiseo M
    Tumour Biol; 2015 Aug; 36(8):5943-51. PubMed ID: 25731731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations.
    Yanwei Z; Bo J; Yuqing L; Rong L; Xueyan Z; Song H; Baohui H
    J Cancer Res Ther; 2016; 12(1):254-8. PubMed ID: 27072247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].
    Chen H; Yang X; Liu H; Ma K; Zhong J; Dong Z; Zhuo M; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):589-597. PubMed ID: 28935011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
    Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
    Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
    Tsujino K; Kawaguchi T; Kubo A; Aono N; Nakao K; Koh Y; Tachibana K; Isa S; Takada M; Kurata T
    J Thorac Oncol; 2009 Aug; 4(8):994-1001. PubMed ID: 19633474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib.
    Fiala O; Pesek M; Finek J; Racek J; Minarik M; Benesova L; Bortlicek Z; Sorejs O; Kucera R; Topolcan O
    Neoplasma; 2016; 63(3):471-6. PubMed ID: 26952513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study.
    Arrieta O; Villarreal-Garza C; Martínez-Barrera L; Morales M; Dorantes-Gallareta Y; Peña-Curiel O; Contreras-Reyes S; Macedo-Pérez EO; Alatorre-Alexander J
    BMC Cancer; 2013 May; 13():254. PubMed ID: 23697613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.